Serzone Litigation

Serzone is an antidepressant medication developed by Bristol-Myers Squibb, which was approved for sale in the United States in 1994. Serzone was often prescribed for depression combined with anxiety.

Following reports of liver failure in Serzone users, the FDA required Bristol-Myers to place a "black box" warning on Serzone's packet insert.

Serzone was withdrawn from the market in Europe in January, 2003, and in Canada in November, 2003.

In early 2004, the safety watchdog organization Public Citizen filed a lawsuit intended to force the FDA to withdraw Serzone from the market.

In May, 2004, Bristol-Myers announced that it would stop manufacturing Serzone for "business" reasons, although it continues to insist that the drug was perfectly safe.

Copyright © 2004 Aaron Larson, All rights reserved. No portion of this article may be reproduced without the express written permission of the copyright holder. If you use a quotation, excerpt or paraphrase of this article, except as otherwise authorized in writing by the author of the article you must cite this article as a source for your work and include a link back to the original article from any online materials that incorporate or are derived from the content of this article.

This article was last reviewed or amended on Apr 26, 2018.